compare the efficacy of High-Velocity Nasal Insufflation (HVNI) versus ContinuousPositive Airway Pressure (CPAP) in managing COVID 19 pneumonic patients with acute type 1respiratory failure
A prospective randomized controlled trial was conducted on 108 patients with COVID 19
pneumonia with acute hypoxemic respiratory failure at Mansoura University Hospitals to
compare the efficacy of High-Velocity Nasal Insufflation (HVNI) versus Continuous
Positive Airway Pressure (CPAP) in managing COVID 19 pneumonic patients with acute type 1
respiratory failure, focusing on the need for invasive mechanical ventilation (IMV) and
28-day mortality. Patients were randomized into two equal groups: HVNI group and CPAP
group. Baseline characteristics, respiratory parameters, and clinical outcomes were
recorded.
Device: High Velocity Nasal Insufflation
COVID 19 Pneumonic Patients with Acute Type 1 Respiratory Failure received High Velocity
Nasal Insufflation
Device: Continuous Positive Airway Pressure
COVID 19 Pneumonic Patients with Acute Type 1 Respiratory Failure received Continuous
Positive Airway Pressure
Inclusion Criteria:
- Patients aged above 18 years with COVID 19 pneumonia with acute type 1 respiratory
failure were included.
Exclusion Criteria:
- patients with hypercapnic respiratory failure.
- patients with a disturbed level of consciousness and/or a high risk of aspiration
- individuals with hypotension
- patients requiring invasive mechanical ventilation.
Mohamed AbdElmoniem
Al Mansurah 360761, Egypt
Mohamed AbdElmoniem, Principal Investigator
Lecturer of chest medicine faculty of medicine Mansoura university